HYPERTENSIONJNC7,8.ppt
-
Upload
duaa-maqbool -
Category
Documents
-
view
7 -
download
0
description
Transcript of HYPERTENSIONJNC7,8.ppt
![Page 1: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/1.jpg)
HYPERTENSION
![Page 2: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/2.jpg)
![Page 3: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/3.jpg)
JNC 7
![Page 4: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/4.jpg)
Classification of Blood Pressure
CATEGORY SBP (mmHg) DBP (mmHg)
Normal <120 and <80
Prehypertension
120-139 or 80-89
Hypertension, Stage 1
140-159 or 90-99
Hypertension, Stage 2
≥160 or ≥100
**At least 2 readings on separate occasions to diagnose hypertension
![Page 5: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/5.jpg)
DIAGNOSTIC WORKUP
Assess risk factors and co- morbidities Reveal identifiable causes of hypertension Assess presence of target organ damage Conduct history and physical examination Obtain laboratory tests: Urinalysis, Blood
glucose, hematocrit, Lipid panel, Serum potassium, Creatinine, and Calcium. Optional: urinary albumin/creatinine ratio
Obtain Electrocardiogram
![Page 6: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/6.jpg)
TARGET ORGAN DAMAGE: JNC VII express
Heart Left ventricular hypertrophy Angina or prior myocardial infarction Prior coronary revascularization Heart failure
Brain Stroke or transient ischemic attack
Chronic kidney disease Peripheral arterial disease Retinopathy
![Page 7: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/7.jpg)
ASSESS FOR MAJOR CVD RISK FACTORS Hypertension Obesity Dyslipidemia Diabetes mellitus Cigarette smoking Physical inactivity Microalbuminuria, estimated GFR
<60mL/miin Age (>55 for men, >65 for women) Family history of premature CVD (men
age<55, women age <65
![Page 8: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/8.jpg)
ASSESS FOR IDENTIFYABLE CAUSES OF HYPERTENSION Sleep apnea Drug induced/related Chronic kidney disease Primary aldosteronism Renovascular disease Cushing’s syndrome or steroid therapy Pheochromocytoma Coarctation of aorta Thyroid/Parathyroid disease
![Page 9: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/9.jpg)
PRINCIPLES OF HYPERTENSION TREATMENT
Treat to BP <140/90 or BP < 130/80 in patients with diabetes or CKD
Majority of patients will require two medication to reach goal.
![Page 10: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/10.jpg)
![Page 11: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/11.jpg)
JNC 8
![Page 12: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/12.jpg)
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults(JNC 8)
RECOMMENDATION 1
In the general population aged ≥60 years old, initial pharmacologic treatment to lower BP at SBP of ≥150mmHg or DBP of ≥90mmHg and treat to a goal SBP <150mmHg and goal DBP <90mmHg
Strong recommendation- Grade A
![Page 13: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/13.jpg)
RECOMMENDATION 2
In the general population <60 years, initiate pharmacologic treatment to lower BP at DBP 90mmHg and treat to a goal DBP <90mmHg.
For ages 30-59 years, Strong Recommendation – Grade A
For ages 18-29 years,Expert Opinion – Grade E
![Page 14: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/14.jpg)
RECOMMENDATION 3
In the general population <60 years, initiate pharmacologic treatment to lower BP at SBP140 mm Hg and treat to a goal SBP <140 mm Hg.
Expert Opinion – Grade E
![Page 15: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/15.jpg)
RECOMMENDATION 4
In the population aged ≥18 years with CKD, initiate pharmacologic treatment to lower BP at SBP ≥140mmHg or DBP ≥90 mmHg and treat to a goal SBP <140mmHg and goal DBP <90mmHg
Expert opinion- grade E
![Page 16: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/16.jpg)
RECOMMENDATION 5
In the population aged ≥18 years with diabetes, initiate pharmacologic treatment to lower BP at SBP ≥140mmHg or DBP ≥90 mmHg and treat to a goal SBP <140mmHg and goal DBP <90mmHg
Expert opinion grade E
![Page 17: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/17.jpg)
RECOMMENDATION 6
In the general non black population, including those with diabetes, initial antihypertensive treatment should include a thiazide type diuretic, calcium channel blocker, angiotensin- converting enzyme inhibitor or angiotensic receptor blocker.
Moderate recommendations grade B
![Page 18: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/18.jpg)
RECOMMENDATION 7 In the general black population,
including those with diabetes, initial antihypertensive treatment should include a thiazide type diuretic or calcium channel blocker For general black population: Moderate
recommendations- grade B for black patients with diabetes: weak
recommendation- grade C
![Page 19: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/19.jpg)
RECOMMENDATION 8 In the population aged ≥18 years
with CKD, initial (or add on) antihypertensive treatmet should include an ACEi or ARB to improve kidney outcomes. This applies to all CKD patients with hypertension regardless of race or diabetes status. Moderate recommendation- grade B
![Page 20: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/20.jpg)
RECOMMENDATION 9 The main objective of hypertension
treatment is to attain and maintain goal BP. If goal BP is not reached within a month of treatment, increase the dose of the initial drug or add a second drug from one of the classes in recommendation 6 ( TTD, CCB, ACEI or ARB). The clinician should continue to assess BP and adjust the treatment regimen until goal BP is reached.
![Page 21: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/21.jpg)
RECOMMENDATION 9 contin. If goal BP cannot be reached with 2
drugs, add and titrate a third drug from the list provided. Do not use an ACEi and an ARB together in the same patient. If goal BP cannot be reached using only the drugs in recommendation 6 because of a contraindication or the need to use more than 3 drugs to reach goal BP, antihypertensives from other classes can be used.
![Page 22: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/22.jpg)
RECOMMENDATION 9 contin. Referral to a hypertension specialist
may be indicated for patients in whom goal BP cannot be attained using the above strategy or for the management of complicated patients for whom additional clinical consultation is needed. Expert opinion –grade E
![Page 23: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/23.jpg)
DOSAGE
![Page 24: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/24.jpg)
![Page 25: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/25.jpg)
Indications for major classes of AHD
![Page 26: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/26.jpg)
Choice of AHD in patients with concomitant disease.
![Page 27: HYPERTENSIONJNC7,8.ppt](https://reader036.fdocuments.net/reader036/viewer/2022081603/55cf949f550346f57ba3491f/html5/thumbnails/27.jpg)
THANK YOU!